Per vaginal use of peel of pomegranate in uterovaginal prolapse
Phase 2
- Conditions
- Health Condition 1: N814- Uterovaginal prolapse, unspecified
- Registration Number
- CTRI/2024/08/072270
- Lead Sponsor
- State Takmeel Uttib College and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Married females above 30 years with 1st and 2nd degree POP-Q
Exclusion Criteria
Pregnant & Lactating women
Women with systemic illness and other endocrinal disorders
Women with pelvic pathologies and suspected malignancies
Women on hormonal therapies or IUCDs
Chronic inversion and congenital elongation of cervix
Women with 3rd and 4th degree of uterine prolapse
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of pomegranate peel in uterovaginal prolapse treatment?
How does pomegranate peel compare to standard-of-care treatments for uterovaginal prolapse in clinical outcomes?
Are there specific biomarkers that predict response to pomegranate peel therapy in uterovaginal prolapse patients?
What are the potential adverse events associated with per vaginal application of pomegranate peel and their management strategies?
What related compounds or combination therapies show promise in treating uterovaginal prolapse alongside pomegranate peel?